Meeting
2015 Gastrointestinal Cancers Symposium
Drug cost and outcome in metastatic colorectal cancer with emphasis on monoclonal antibodies.
Authors
Helmy M. Guirgis
University of California, Irvine, Irvine, CA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 567)
DOI
10.1200/jco.2015.33.3_suppl.567
Abstract #
567
Poster Bd #
B11
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
First-line biological agents plus chemotherapy in elderly patients with metastatic colorectal cancer: A retrospective pooled analysis.
First Author: Pilar Garcia-Alfonso
Poster
2017 Gastrointestinal Cancers Symposium
Effect of subsequent chemotherapy on overall survival in first-line chemotherapy with targeted agents for patients with metastatic colorectal cancer: Systematic review and meta-analysis of randomized control trials.
First Author: Daisuke Sakai
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer.
First Author: William Phillips
Poster
2023 ASCO Annual Meeting
Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort.
First Author: Joan Maurel